iShares U.S. Pharmaceuticals ETF

Find Ratings Reports
IHE : NAL : Financial
$149.9299 | %
Today's Range: 149.2248 - 150.32
Avg. Daily Volume: 40500.0
03/24/17 - 3:59 PM ET
  • Last Ratings Update:02/28/2017
  • Price as of 02/28/2017 :$153.26
  • Net Assets:$737.5 Million
  • NAV:$154.95
  • Premium-1.09%
  • Peer Rank:15 of 35
  • Investment Rating:C
  • Performance:C+
  • RiskC+
IHE Price Chart


We rate iShares US Pharmaceuticals ETF at C. Positive factors that influence this rating include a greater than above average total return, low price volatility, low expense structure and long term portfolio management tenure. The fund invests approximately 99% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.


Total return ranks above peers over the last three years. The iShares US Pharmaceuticals ETF has returned an annual rate of 12.50% since inception. More recently, the fund has generated a total return of 15.60% in the last five years, 7.07% in the last three years, and 12.50% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 92% of them. It has also outpaced 63% of its competitors on a three year basis and 42% of them over the last year for the period ending 2/28/2017. On a year to date basis, IHE has returned 9.54%.

Downside risk has been below average. IHE has a draw down risk of -25.03%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 18.1%. This fund has experienced a high level of volatility in its monthly performance over the last 36 months. As of 2/28/2017, the fund was trading at a price of $153.26, which is 1.6% below its 52-week high of $155.68 and 8.2% above its 52-week low of $141.59.

Low expense ratio helps performance. On total assets of $737.50 million, IHE maintains a low expense ratio compared to its Sector - Health/Biotechnology peers of just 0.44% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As IHE is an exchange traded fund, it has no front end or back end load.

The iShares US Pharmaceuticals ETF is managed by Diane Hsiung at BlackRock Fund Advisors. This fund is one of 306 BlackRock Fund Advisors exchange-traded funds launched since 3/12/1996 that we track.

Latest Stock Upgrades/Downgrades